Sarepta Stock Just Soared 40%. Here’s Why. - Barron's
1. Sarepta resumes Elevidys shipments, boosting premarket stock by 24%. 2. Safety concerns led to a pause in shipments after deaths linked to the drug. 3. Analysts' ratings on SRPT are mixed, with increasing price targets. 4. Stock has dropped 90% over the past year despite resuming sales. 5. Cantor Fitzgerald remains neutral, citing ongoing safety concerns.